Système de Barres pour Implants CY-CAD inc. – Trademark Portfolio

Entity Type: 03

Système de Barres pour Implants CY-CAD inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 3 Nice Classification classes. The owner is based in Québec (Québec).

bureau 106 C

Québec (Québec) G1W4Y5 , CA

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CY-CAD
CY-CAD
Cancelled 2011
CY-CAD
CY-CAD
Cancelled 2011

Trademark Classifications

Système de Barres pour Implants CY-CAD inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

40
Treatment & Processing (2 filings)

Treatment of materials

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Système de Barres pour Implants CY-CAD inc. have?

Système de Barres pour Implants CY-CAD inc. has 2 U.S. trademarks filed with the USPTO.

What trademark classes does Système de Barres pour Implants CY-CAD inc. file in?

Système de Barres pour Implants CY-CAD inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is Système de Barres pour Implants CY-CAD inc.'s trademark registration success rate?

Système de Barres pour Implants CY-CAD inc. has a 0% trademark registration rate, with 0 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.